The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement
Lucia Moiola(Vita-Salute San Raffaele University), Agostino Riva(ASST Fatebenefratelli Sacco), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Massimo Galli(Luigi Sacco Hospital), Simone Vasilij Benatti(Ospedale San Paolo), Carla Tortorella(Carlo Forlanini Hospital), Massimo Origoni(Vita-Salute San Raffaele University), Cristina Scarpazza(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Ruggero Capra(Presidio Ospedaliero), Gıancarlo Comı(Casa di Cura Columbus), Valeria Barcella, Luca Meroni(Luigi Sacco Hospital), Marco Capobianco(Ospedale San Luigi Gonzaga), Fabio Franzetti(Luigi Sacco Hospital), Luca Prosperini(Nini Hospital), Paola Cinque(University of California San Diego), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Maria Michela Fasolo(ASST Fatebenefratelli Sacco), Simonetta Gerevini(Ospedale Papa Giovanni XXIII)
Cited by 48
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
|Journal of Neuroinflammation|2016|896
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706